Old Web
English
Sign In
Acemap
>
authorDetail
>
Thomas Shoemaker
Thomas Shoemaker
Rush University Medical Center
Medicine
Liothyronine
Tolerability
Pediatrics
Multiple sclerosis
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
The rare case of a 20-year-old male with rapidly progressive primary angiitis of the CNS with a good outcome.
2020
Neuroimmunology and Neuroinflammation
Edith Graham
Thomas Shoemaker
Dusan Stefoski
Marinos Kontzialis
Anam Naumaan
Rajeev K. Garg
Show All
Source
Cite
Save
Citations (0)
A Phase 1b, open-label study to evaluate the safety and tolerability of the putative remyelinating agent, liothyronine, in individuals with multiple sclerosis (S56.003)
2019
Neurology
Scott D. Newsome
Thomas Shoemaker
Fan Tian
Kate Fitzgerald
Pavan Bhargava
Sarah Snoops
David S. Cooper
Jennifer S. Mammen
Ellen M. Mowry
Peter A. Calabresi
Show All
Source
Cite
Save
Citations (0)
A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with Multiple Sclerosis
2019
Scott D. Newsome
Thomas Shoemaker
Pavan Bhargava
Sarah Snoops
Fan Tian
Kathryn C. Fitzgerald
David S. Cooper
Jennifer S. Mammen
Ellen M. Mowry
Peter A. Calabresi
Show All
Source
Cite
Save
Citations (0)
1